UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Removal of Carbapenem-Resistant Enterobacteriaceae (CRE) from blood by heparin-functional hemoperfusion media

PloS one, 2014-12, Vol.9 (12), p.e114242-e114242

2014

Volltextzugriff (PDF)

Removal of clinically relevant SARS-CoV-2 variants by an affinity resin containing Galanthus nivalis agglutinin

PloS one, 2022-07, Vol.17 (7), p.e0272377-e0272377

2022

Volltextzugriff (PDF)

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression

The Lancet infectious diseases, 2012-09, Vol.12 (9), p.678-686

2012

Volltextzugriff (PDF)

Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials

Critical care medicine, 2016-08, Vol.44 (8), p.1461-1467

2016

Volltextzugriff (PDF)

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial

JAMA : the journal of the American Medical Association, 2013-03, Vol.309 (11), p.1154

2013

Volltextzugriff (PDF)

Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis

Critical care medicine, 2010-01, Vol.38 (1), p.72-83

2010

Volltextzugriff (PDF)

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

The New England journal of medicine, 2001-03, Vol.344 (10), p.699-709

2001

Volltextzugriff (PDF)

White Paper: Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial Pathogens

Clinical infectious diseases, 2012-10, Vol.55 (8), p.1031-1046

2012

Volltextzugriff (PDF)

Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor-α Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Septic Shock: Randomized, Double-Blind, Placebo-Controlled Phase IIb Study

Critical care medicine, 2014-03, Vol.42 (3), p.504-511

2014

Volltextzugriff (PDF)

Time for Well-Powered Controlled Prospective Studies to Test a Causal Role for Herpes Viruses in Alzheimer’s Disease Using Antiherpetic Drugs

The journals of gerontology. Series A, Biological sciences and medical sciences, 2020-05, Vol.75 (6), p.1058-1060

2020

Volltextzugriff (PDF)

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

American journal of respiratory and critical care medicine, 2013-05, Vol.187 (10), p.1041-1043

2013

Volltextzugriff (PDF)

Removal of COVID-19 Spike Protein, Whole Virus, Exosomes, and Exosomal MicroRNAs by the Hemopurifier® Lectin-Affinity Cartridge in Critically Ill Patients With COVID-19 Infection

Frontiers in medicine, 2021-10, Vol.8, p.744141-744141

2021

Volltextzugriff (PDF)

Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis

Expert review of anti-infective therapy, 2011-05, Vol.9 (5), p.507-520

2011

Volltextzugriff (PDF)

Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis

Shock (Augusta, Ga.), 2011-10, Vol.36 (4), p.327-331

2011

Volltextzugriff (PDF)

Activated protein C for H1N1 influenza? More work to do

Critical care (London, England), 2010-01, Vol.14 (3), p.156-156

LaRosa, Steven P

2010

Volltextzugriff (PDF)

A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

Critical care (London, England), 2009-01, Vol.13 (2), p.R36-R36, Article R36

2009

Volltextzugriff (PDF)

Biomarkers: The Future

Critical care clinics, 2011-04, Vol.27 (2), p.407-419

2011

Volltextzugriff (PDF)

Drotrecogin alfa (activated) in severe sepsis – Authors' reply

The Lancet infectious diseases, 2013-02, Vol.13 (2), p.110-111

2013

Volltextzugriff (PDF)

Year in review 2008: Critical Care--sepsis

Critical care (London, England), 2009-01, Vol.13 (5), p.224-224

2009

Volltextzugriff (PDF)

Sepsis Strategies in Development

Clinics in chest medicine, 2008-12, Vol.29 (4), p.735-747

2008

Volltextzugriff (PDF)

Should Prophylaxis for Pneumocystis carinii Pneumonia in Solid Organ Transplant Recipients Ever Be Discontinued?

Clinical infectious diseases, 1999-02, Vol.28 (2), p.240-246

1999

Volltextzugriff (PDF)

Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)

Clinical infectious diseases, 2003-07, Vol.37 (1), p.50-58

2003

Volltextzugriff (PDF)

Immune Aspects of Sepsis and Hope for New Therapeutics

Current infectious disease reports, 2012-10, Vol.14 (5), p.474-483

2012

Volltextzugriff (PDF)

Clinical and Laboratory Diagnosis of Central Nervous System Histoplasmosis

The American journal of medicine, 2012-10, Vol.125 (10), p.e1-e2

2012

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(74)

Publikationsform

Sprache

Englisch
(86)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Removal of Carbapenem-Resistant Enterobacteriaceae (CRE) from blood by heparin-functional hemoperfusion media

Removal of clinically relevant SARS-CoV-2 variants by an affinity resin containing Galanthus nivalis agglutinin

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression

Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation

Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

White Paper: Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial Pathogens

Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor-α Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Septic Shock: Randomized, Double-Blind, Placebo-Controlled Phase IIb Study

Time for Well-Powered Controlled Prospective Studies to Test a Causal Role for Herpes Viruses in Alzheimer’s Disease Using Antiherpetic Drugs

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

Removal of COVID-19 Spike Protein, Whole Virus, Exosomes, and Exosomal MicroRNAs by the Hemopurifier® Lectin-Affinity Cartridge in Critically Ill Patients With COVID-19 Infection

Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis

Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis

Activated protein C for H1N1 influenza? More work to do

A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

Biomarkers: The Future

Drotrecogin alfa (activated) in severe sepsis – Authors' reply

Year in review 2008: Critical Care--sepsis

Sepsis Strategies in Development

Should Prophylaxis for Pneumocystis carinii Pneumonia in Solid Organ Transplant Recipients Ever Be Discontinued?

Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)

Immune Aspects of Sepsis and Hope for New Therapeutics

Clinical and Laboratory Diagnosis of Central Nervous System Histoplasmosis

Suchergebnisse filtern